Canurta Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
mississauga, ontario, canada
Type:
sample
Technology:
sample
sample
About: Canurta Therapeutics is a preclinical biotechnology company founded in 2021, focused on developing botanically derived therapeutics for inflammatory and neurological diseases. The company specializes in rare polyphenols, particularly cannflavins A and B, to address unmet medical needs in neurology, virology, oncology, and immunology.
Utilizing its proprietary Polykye™ Platform, Canurta extracts and develops polyphenol-based therapies. Its lead asset, CNR-401, targets amyotrophic lateral sclerosis (ALS) and is set to enter Phase 2 clinical trials in 2025. The company is also exploring applications in nutraceuticals and functional health products. Canurta is preparing for a TSXV listing in 2025, aiming to expand investor access and support its growth strategy. With a strong leadership team and a focus on partnerships, Canurta is committed to advancing research and commercialization in the field of botanical therapeutics.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Canurta Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.